pharyngotonsillitis
Conditions
Interventions
All patients with clinical suspicion of pharyngotonsillitis will be examined and investigated for fever, tonsillar hypertrophy, tonsillar exudates, anterior cervical adenomegaly, mucosal lesions (pete
polymerase chain reaction for Fusobacterium necrophorum (Bank F et al., 2010) and panel detection of respiratory viruses by polymerase chain reaction (influenza A and B viruses, adenovirus, Rhinovirus
Group A2 = Antibiotic therapy + placebo of photodynamic therapy
Group B1 = Photodynamic therapy
Group B2 = Placebo of photodynamic therapy.
A total of 1.2 x (22 + 82) = 125 patients should be included. Thus, the distribution of a total of 126 patients will be:
Group A1: 13 patients
Group A2: 13
Drug
Device
G06.099.050
C07.550.781
C07.550.781.750
E02.186.500
Sponsors
Universidade de São Paulo
Universidade de São Paulo
Eligibility
Age
18 Years to 45 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: Age between 18a and 45a; Signature of the Informed Consent Form; Presence of fever> 38ºC, oropharyngeal hyperemia, hypertrophy or presence of exudate in palatine tonsils.
Exclusion criteria
Exclusion criteria: Exclusion Criteria: Use of antibiotics in the 24 hours prior to admission without protocol; Clinical therapy using the antibiotic (sepsis, peritonsillar abscess, heart failure, immunodeficiency, clinical suspicion of Lemierre's syndrome).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| First expected outcome: negativation of counting colonies of EBHGA in culture of oropharyngeal swabs, verified after five minutes and after two days of intervention;Second expected outcome: fever resolution, verified by the rate of fever resolution in two days of treatment, and by the number of days until the fever resolution.;Third expected outcome: pain relief, as assessed by pain relief rate at two days of treatment, and by number of days until resolution of sore throat. | — |
Secondary
| Measure | Time frame |
|---|---|
| The secondary endpoints aim in particular to verify if there is a decrease in the rate of complications, measured by the rate of occurrence of Lemierre syndrome (septic thrombophlebitis), by the rate of evolution with peritonsillar abscess in two weeks; by the post-streptococcal GNDA development rate at one month, and by the frequency of development rheumatic fever at two months.;Another secondary outcome observed is whether there is a reduction in the number of pharyngotonsillitis recurrences in two months | — |
Countries
Brazil
Contacts
Public ContactKate;Vanderlei Blanco;Bagnato
Universidade de São Paulo;Universidade de São Paulo
Outcome results
None listed